Brought to you by 
Bayer HealthCare licenses Isis' Antisense Thrombosis Candidate; Agreement Amended to Include IONIS-FXI-LRx
11 Nov 2022
Executive Summary
Bayer HealthCare Pharmaceuticals AG licensed exclusive development and commercialization rights to Isis Pharmaceuticals Inc.'s ISIS-FXIRx (formerly ISIS416858), a Factor XI inhibitor in Phase II for thrombosis prevention.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer HealthCare licenses Isis' Antisense Thrombosis Candidate; Agreement Amended to Include IONIS-FXI-LRx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice